Clinical Trials

The purpose of this study is to assist patients and clinicians in discussing the potential benefits and side effects of treatment of familial hypercholesterolemia (FH) and to develop a decision aid for use in a clinical setting.

The purpose of this study is to identify individuals who may have a condition called Familial Hypercholesterolemia (FH) by using different datasets and methodologies.

The CASCADE Familial Hypercholesterolemia Registry will track therapy, clinical outcomes, and patient-reported outcomes over time aiming to increase familial hypercholesterolemia awareness, promote optimal disease management, and improve outcomes. This study is not recruiting family members of FH patients at this time.

The purpose of this study is to develop a registry of molecularly confirmed Familial Hypercholesterolemia (FH) cases in conjunction with the retrospective FHIRE study (IRB# 18-009654) in order to identify and offer genetic testing to Mayo Clinic patients with suspected FH.

Develop a biobank of samples from patients undergoing therapy with PCSK9 inhibitors (FDA- approved in 2015, therapeutics for hypercholesterolemia) with the goal of developing laboratory tests which may help identify best candidates for these therapies and aid in monitoring therapy efficacy.

The purpose of this study is to conduct a genomic medicine implementation project to establish mechanisms for return of actionable findings from targeted sequencing of ~109 disease-relevant genes and genotyping of select polymorphisms in a large study setting (eMERGE III consortium). A primary focus of the Mayo group will be on two common actionable genetic disorders–familial hyperlipidemia (FH) and familial colorectal cancer (CRC).

The purpose of this study is to form processes to get findings from targeted gene sequencing that can be acted on using two common actionable genetic disorders–familial hyperlipidemia and familial colorectal cancer.